Editorial: Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma
Language English Country England, Great Britain Media print
Document type Editorial
PubMed
38655820
DOI
10.1111/his.15181
Knihovny.cz E-resources
- MeSH
- Endopeptidases MeSH
- Neoplasm Invasiveness pathology MeSH
- Humans MeSH
- Membrane Proteins metabolism MeSH
- Adenocarcinoma, Mucinous * pathology mortality metabolism MeSH
- Biomarkers, Tumor * metabolism analysis MeSH
- Ovarian Neoplasms * pathology mortality MeSH
- Serine Endopeptidases metabolism MeSH
- Thrombospondins metabolism MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Editorial MeSH
- Names of Substances
- Endopeptidases MeSH
- fibroblast activation protein alpha MeSH Browser
- Membrane Proteins MeSH
- Biomarkers, Tumor * MeSH
- Serine Endopeptidases MeSH
- thrombospondin 2 MeSH Browser
- Thrombospondins MeSH
Department of Pathology Belfast Health and Social Care Trust Belfast UK
Department of Pathology Brigham and Women's Hospital Boston MA USA
See more in PubMed
Peres LC, Cushing‐Haugen KL, Köbel M et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J. Natl. Cancer Inst. 2019; 111; 60–68.
Köbel M, Kalloger SE, Huntsman DG et al. Differences in tumor type in low‐stage versus high‐stage ovarian carcinomas. Int. J. Gynecol. Pathol. Off. J. Int. Soc. Gynecol. Pathol. 2010; 29; 203–211.
Gilks CB, Selinger CI, Davidson B et al. Data set for the reporting of ovarian, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Int. J. Gynecol. Pathol. 2022; 41(Suppl 1); S119–S142.
Busca A, Nofech‐Mozes S, Olkhov‐Mitsel E et al. Histological grading of ovarian mucinous carcinoma—an outcome‐based analysis of traditional and novel systems. Histopathology 2020; 77; 26–34.
Momeni‐Boroujeni A, Song H, Irshaid L, Strickland S, Parra‐Herran C, Busca A. Outcome‐based validation of confluent/Expansile versus infiltrative pattern assessment and growth‐based grading in ovarian mucinous carcinoma. Am. J. Surg. Pathol. 2022; 46; 1250–1259.
Köbel M, Kang EY, Lee S et al. Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma. Histopathology 2023.
Gouy S, Saidani M, Maulard A et al. Characteristics and prognosis of stage I ovarian mucinous tumors according to expansile or infiltrative type. Int. J. Gynecol. Cancer 2018; 28; 493–499.
Muyldermans K, Moerman P, Amant F, Leunen K, Neven P, Vergote I. Primary invasive mucinous ovarian carcinoma of the intestinal type: importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases. Eur. J. Cancer 2013; 49; 1600–1608.
Chen S, Leitao MM, Tornos C, Soslow RA. Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion. Mod. Pathol. 2005; 18; 903–911.
Ludwick C, Gilks CB, Miller D, Yaziji H, Clement PB. Aggressive behavior of stage I ovarian mucinous tumors lacking extensive infiltrative invasion: a report of four cases and review of the literature. Int. J. Gynecol. Pathol. Off. J. Int. Soc. Gynecol. Pathol. 2005; 24; 205–217.
Genestie C, Auguste A, Al Battal M et al. Histological classification of mucinous ovarian tumors: inter‐observer reproducibility, clinical relevance, and role of genetic biomarkers. Virchows Arch. 2021; 478; 885–891.
Meagher NS, Gorringe KL, Wakefield M et al. Gene‐expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2022; 28; 5383–5395.
Parra‐Herran C, Lerner‐Ellis J, Xu B et al. Molecular‐based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups. Mod. Pathol. 2017; 30; 1748–1759.
Krämer P, Talhouk A, Brett MA et al. Endometrial cancer molecular risk stratification is equally prognostic for endometrioid ovarian carcinoma. Clin. Cancer Res. 2020; 26; 5400–5410.
D'Alessandris N, Travaglino A, Santoro A et al. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: a quantitative systematic review. Gynecol. Oncol. 2021; 163; 427–432.
Parra‐Herran C, Bassiouny D, Lerner‐Ellis J et al. p53, mismatch repair protein, and POLE abnormalities in ovarian clear cell carcinoma: an outcome‐based Clinicopathologic analysis. Am. J. Surg. Pathol. 2019; 43; 1591–1599.
Irshaid L, Costigan DC, Dong F, Matulonis UA, Nucci MR, Kolin DL. Molecular landscape of mullerian clear cell carcinomas identifies the cancer genome atlas‐like prognostic subgroups. Mod. Pathol. 2023; 36; 100123.
